Phynova Share Discussion Threads

[mike111d] 24/8/2009 20:35

Cancellation notice issued this morning as planned.

[andrbea] 31/7/2009 14:18

best stay out IMO

it's delisting (24.8.09)

nia dyor

[pahee2] 31/7/2009 14:10

its going to 5p end of next week

[double6] 07/7/2009 15:54

Well - we're now down to a MC of around £600k.

Recent share placing at 6p (with warrants at 10p) - currently 2.375p!

Will those who took up the placing be regretting things ??

[mal124] 03/12/2007 09:56

Phynova Group PLC said preliminary data from the phase I/II trials of its lead drug candidate PYN17, for treating chronic hepatitis C, successfully confirms its safety and tolerability.

The company said the results show that PYN17 was well tolerated, with a low level of relatively minor adverse events identical to those seen with a placebo.

The developer of drugs derived from Chinese botanical medicines said it expects to commence the phase IIb study for PYN17 in the first half of 2008.

[mal124] 03/12/2007 09:54

Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, today announces that its Business Development Director, Dr Tony Mills, will provide an update on its plant-derived antibacterial PYN6 at the natural products conference "Natural Products in Drug Discovery and Development" at the Holiday Inn, Munich City Centre on Tuesday, 4 December. Results from pre-clinical work conducted by Phynova in collaboration with the University of East London have demonstrated a high degree of bacterial inhibition against 30 common strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from London's teaching hospitals. Inhibition was demonstrated against all of the strains of MRSA that were tested, using levels of PYN6 that were some tenfold less than that typically needed to achieve inhibition with mupirocin, the topical antibiotic currently routinely used for treatment of skin infections involving MRSA. Furthermore resistance to PYN6 has not been observed even after prolonged culture of numerous MRSA strains with PYN6. PYN6 has also shown significant activity against the Propionibacterium acnes organism which causes acne.

Phynova is conducting formulation studies to develop a topical gel, cream or ointment containing PYN6 as active ingredient and is in active discussions with several companies in the dermatological sector regarding the future development and commercialisation of PYN6.

Robert Miller, Phynova's CEO, said: "Gaining access to potentially valuable new drug opportunities such as PYN6 was an important part of the rationale for our cooperation with our Chinese partner Botanic Century. We are delighted that the extensive preclinical work that we have carried out this year has confirmed its promise as a potential treatment for MRSA, the devastating bacterial infection that has become such a problem in the UK. An additional key part of our commercial strategy is to offer a proportion of our drug candidates as in licensing opportunities to the pharma industry so we are also very pleased with the interest that we are attracting from potential partners."

[mal124] 18/6/2007 11:47

highly undervalued company..
one drug for treating hepatitis C already in phase 11 trials in america..another two drug candidates will be in trials by end of year.

HCV(hep c)drug may be introduced before it is accepted in the US and talks are being held in Brazil and Russia already.

[fillyourboot] 06/2/2007 05:16

Big deal signed for Phynova

Phynova teams up with Hong Kong

By Mark Kleinman in Hong Kong

Last Updated: 1:22am GMT 06/02/2007






Phynova, the Aim-listed company searching for cancer cures based on plant extracts, will today announce a collaboration with a Hong Kong organisation affiliated to the city's Jockey Club.

The company, which marks its first anniversary as a UK-listed company this month, is expected to announce in a statement to the London Stock Exchange that it has signed a deal to work with the government-funded Jockey Club Institute of Chinese Medicine on the development of a series of new drugs. The company is relatively small in market value - £13m at yesterday's close - but executives are understood to believe it could be worth ten times that amount within a few years.

Last week, Phynova appointed entrepreneur Karl Watkin as its chairman. Mr Watkin has been involved with several listed companies including D1 Oils, the biodiesel producer, China Goldmines and Dermasalve, a developer of retail dermatology products.

Phynova's agreement in Hong Kong will mark the latest exposure of UK investors to the burgeoning Traditional Chinese Medicine (TCM) sector.

--

[w r] 01/2/2007 18:03

29 January 2007

Phynova's oriental promise

"It's been a busy year," says chief executive Robert Miller. Indeed, since Phynova joined Aim in February 2006 it has won US approval to start clinical studies of PYN17, for hepatitis C symptoms, snapped up a 45 per cent stake in Chinese company Botanic Century and established a Chinese subsidiary. In addition, it has also licensed in PYN22, for fatty liver disease and obesity, and PYN6, an antibacterial agent.

The company is developing drugs from Chinese botanical medicines and plans to commercialise them in the western and Chinese markets. Western pharmaceutical companies are becoming more interested in Chinese medicines – AstraZeneca has built a research and development facility in China - and US regulators recently approved Medigene's botanical drug for genital warts. The hepatitis C market will be worth $9bn in annual sales by 2010 and China is the biggest market.

Mr Miller admits that success in China depends on building key relationships with companies and regulators. But former deputy director of the Chinese regulator, Dr Ren Dequen, recently became Phynova's co-chairman, and the stake in Botanic Century gives it a foothold in China. Mr Miller is also keen to sign licensing deals as early as possible


The shares have been disappointing since the flotation and the portfolio is early stage. But, with enough cash until 2008, they look speculative good value.

[barefoot1] 30/1/2007 12:54

Phynova Appointment of Chairman

RNS Number:2620Q
Phynova Group PLC
29 January 2007


For Immediate Release 29 January 2007



PHYNOVA GROUP PLC


Appointment of Karl Watkin as Chairman


Phynova Group PLC ("Phynova" or the "Group") (AIM: PYN), a developer of
pharmaceuticals derived from Chinese botanical drugs targeting viral and
metabolic diseases and cancer, is pleased to announce the appointment of Karl E
Watkin MBE as Chairman. Karl, appointed as Non-Executive Director on 14 December
2006, replaces John Pool who will continue to act as a Non-Executive Director on
the Board. Both appointments are effective immediately.

Karl brings to the role of Chairman over 25 years experience working in China, a
market critical to Phynova's business strategy and extensive public company
experience. Until earlier this month, Karl was Chairman of D1 Oils plc, a
UK-based global producer of biodiesel, for which he is the founder and received
an MBE for his services to UK exports in 1993. He will remain on the Board as a
Non-Executive Director of D1 Oils. Other current directorships include
Non-Executive Director of China Goldmines plc, a gold resource company with a
direct interest in a gold mining project in the province of Hunan China. Karl
also brings valuable expertise gained from the healthcare sector via Dermasalve
Sciences plc, a developer of retail dermatology products, which he created in
2004, floated in January 2006 and currently serves as a Non-Executive Director.

John Pool has served as Chairman since February 2005, in which time Phynova has
progressed from an early stage private company to an acquisitive publicly listed
company.

Robert Miller, Chief Executive of Phynova, commented: "We are delighted that
Karl has become Chairman of the Board. He brings a great deal of public company
and Chinese experience which will be of great value to the Company as it
progresses through clinical trials this year and further develops its Chinese
operations.

John is an invaluable asset to the Company and I wish to thank him for all his
hard work in moving the Company forward. We are pleased that the Company will
retain his expertise as Non-Executive Director."

Karl Watkin, Chairman of Phynova, commented: "With the recent acceptance of its
IND application to commence clinical trials of PYN17 for Hepatitis C and the
acquisition of Botanical Century in China last year, Phynova is gaining momentum
in both its drug pipeline and expansion into the Chinese market. As such, it is
a very exciting time to be taking up the role of Chairman. I hope that through
my experience in China, I will be able to build on this momentum."

[grupo] 12/7/2006 08:16

Phynova applies for patents for Chinese herb drugs for obesity, hepatitis C

LONDON (AFX) - Phynova Group PLC, which develops pharmaceuticals from
Chinese medicines, said it has filed patent applications for its PYN-22 drug for
obesity and its PYN-18 drug for hepatitis C.
And it said it has signed a letter of intent with a clinical research
organisation to start Phase IIb trials of its lead development product, PYN-17
for hepatitis C.
Chief executive Robert Miller said the company has also strengthened its
management team by appointing Stephen Marshall as chief operating officer and
David Galloway as chief medical officer.

[e-mail]
lam/jm

[rickus] 16/5/2006 07:08

Phynova Group PLC
16 May 2006


For Immediate Release 16 May 2006


Phynova Group PLC

Interim Results
For the Six Months Ended
31 March 2006


Phynova Group PLC ('Phynova' or the 'Group') (AIM : PYN), a developer of
pharmaceuticals derived from Chinese botanical drugs targeting viral and
metabolic diseases and cancer, is pleased to announce maiden interim results for
the six months ended 31 March 2006.


Key Points:


•Successful flotation on AIM in February 2006 having raised £3.65 million
via a placing


•In-license of PYN22, drug candidate targeting obesity


•Positive outcome from pre-clinical testing on PYN18, drug candidate
targeting the Hepatitis C Virus (HCV)


• Additional source of future revenues from a collaboration agreement with
WellGen, Inc. for development of Phynova compounds as nutrigenomic
ingredients for functional foods


John Pool, Chairman of Phynova, commented:


'Our successful flotation is a major stride forward for the Company enabling
us to concentrate fully on the development of our product pipeline. We
believe that the following six months will be an equally exciting period for
the Company in terms of its development and we look forward to updating
shareholders on our progress.'


For further information, please contact:

Phynova Group PLC

Robert Miller, Chief Executive 01865 784880

Nabarro Wells

Marc Cramsie, Director 020 7710 7400

Buchanan Communications

Tim Anderson/Isabel Podda/Amy Rajendran 020 7466 5000


Chairman's and Chief Executive's Review


We are delighted that our introduction to AIM on 27 February 2006 saw the
Company advance its development through a pre-IPO placement, which raised £3.65
million before expenses.


This has allowed Phynova to concentrate on the development of the most advanced
products in its pipeline with a view to moving them into clinical trials within
twelve months.


Strategy


We have established a business model which seeks to reduce the risks, the high
cost and the time taken to develop pharmaceuticals by selecting drug candidates
which are not only derived from existing medicines with proven safety and
efficacy in clinical use in China but also which target large therapeutic
markets in the West where current therapies are either inadequate or
non-existent. We aim to license our intellectual property to major
pharmaceutical companies in return for revenue in the form of upfront payments,
milestone payments and royalties.


We have identified a number of drug candidates in the fields of anti-virals,
anto-microbials, anti-inflammatories and oncology and are currently focusing on
the rapid development of six of these.


o PYN17 for relief of the symptoms of chronic hepatitis C (CHC)

o PYN18 for hepatitis C virus (HCV)

o PYN22 for obesity

o PYN7 for cancer

o PYN6 for antibiotic-resistant bacteria

o PYN5 to treat respiratory tract infections


Portfolio Update


Since our admission to AIM we have continued to work on the development of our
intellectual property both existing and new.


In April we were pleased to announce the positive outcome from third party
testing on PYN18, a novel anti-viral discovered by Phynova's scientists has
shown definite in vitro activity against the hepatitis C virus. Since announcing
these results we have seen significant interest regarding potential partnerships
to drive PYN18 through clinical development. HCV has infected more than 200
million people worldwide and current therapies are often ineffective with
negative side-effects.


We are also pleased to announce that the Company has entered into a
Collaboration Agreement with WellGen, Inc., a life sciences company using
nutrigenomics to discover and develop ingredients for functional foods. This
agreement gives us an exciting opportunity to generate additional revenues from
our research activities. Under the terms of the agreement Phynova will supply
WellGen with sample compounds that demonstrate anti-inflammatory activity from
its existing pipeline, then work to develop these as functional food
ingredients. If successful, royalties will provide a revenue stream in addition
to those from our core business. The size of the functional foods market,
according to MarketResearch.com, is expected to grow to $167 billion globally by
2010.


During the period, good progress has made on the other products in your
Company's pipeline, including the in-licensing of a promising new drug candidate
(PYN22) for the anti-obesity market which is estimated to be worth $5 billion.


Financial Review


In the six months ended 31 March 2006, Phynova recorded a pre-tax loss of
£597,000, which is in line with expectations.


Cash outflow before financing was £609,000 reflecting the loss for the period.
Our cash position remains strong and at 31 March 2006 was £2.9 million following
our successful pre-IPO fund raising. We are pleased to confirm that we continue
to make good use of cash resources and that we remain firmly committed to our
budget.


Summary and Prospects


The progression of our product portfolio has been very encouraging. PYN18 has
clearly demonstrated its potential in all initial testing and we anticipate
taking this candidate into clinical development as rapidly as possible.


Our pre-clinical development program is very active and several of our drug
candidates are the subject of on-going screening work by third parties and we
look forward to announcing the results in due course.


We would like to thank all our shareholders, both existing and new, for their
support. We look forward to the next six months in which we will continue to
make significant strides in the further development of our product pipeline.


John Pool Robert Miller
Chairman Chief Executive Officer


PHYNOVA GROUP PLC

CONSOLIDATED SUMMARISED PROFIT AND LOSS ACCOUNT


For the six months ended 31 March 2006


6 months 6 months 15 months
Ended Ended Ended
31 March 2006 31 March 2005 30 September 2005
Note Unaudited Unaudited Audited
£'000 £'000 £'000

Turnover - - -

Cost of sales -
research and
development (160) (111) (243)

Gross Loss (160) (111) (243)

Administrative expenses
Administrative expenses (315) (139) (364)
Aim Listing expenses (130) - -
Total administrative
expenses (445) (139) (364)

Operating loss (605) (250) (607)

Interest receivable 8 - -

Loss on ordinary
activities before and
after taxation (597) (250) (607)

Basic and diluted loss
per share 2 (6.5p) (3.7p) (8.7)p


All amounts relate to continuing operations.

There were no recognised gains or losses other than the loss for the financial
period.


PHYNOVA GROUP PLC

CONSOLIDATED SUMMARISED BALANCE SHEET

AS AT 31 MARCH 2006


At At At
31 March 2006 31 March 2005 30 September 2005
Note Unaudited Unaudited Audited
£'000 £'000 £'000

Fixed assets
Tangible assets 3 2 2

Current assets
Debtors 215 58 204
Cash at bank and in
hand 2933 105 29
3148 163 233

Creditors: amounts
falling 217 224 217
due within one year

Net current
assets/(liabilities) 2931 (61) 16

Total assets less
current liabilities 2934 (59) 18
Provision for
liabilities and charges (236) (94) (236)
Net assets/
(liabilities) 2698 (153) (218)

Capital and reserves
Called up share capital 148 71 76
Share premium account 3860 226 419
Merger difference
reserve 642 642 642
Profit and loss account (1952) (1092) (1355)
Shareholders'
funds/(deficit) 3 2698 (153) (218)


PHYNOVA GROUP PLC


CONSOLIDATED SUMMARISED CASH FLOW STATEMENT


AS AT 31 MARCH 2006

6 months 6 months 15 months
Ended Ended Ended
31 March 31 March 30
2006 2005 September
2005
Note Unaudited Unaudited Audited
£'000 £'000 £'000

Net cash (outflow) from
operating activities 4 (615) (178) (453)

Returns on investments and servicing of - -
finance
Interest received 8 - -
Net cash inflow from returns
on investments and servicing
of finance 8 - -
Capital expenditure and financial
investment
Purchase of tangible fixed
assets (2) - (1)
Net cash (outflow) from
capital expenditure and
financial investment (2) - (1)
Cash outflow before
financing (609) (178) (454)

Financing
Issue of ordinary share
capital 3733 231 429
Share Issue expenses (220) - -
Net cash inflow from
financing 3513 231 429
Increase in cash 2904 53 (25)


NOTES TO THE INTERIM STATEMENT


For the six months ended 31 March 2006


1. BASIS OF PREPARATION


The consolidated interim financial statements have been prepared in accordance
with applicable accounting standards and under the historical cost convention.
The principal accounting policies of the group have remained unchanged from
those set out in Phynova Group plc 2005 financial statements except for the
adoption of FRS21 'Events after the balance sheet date' and FRS 25 'Financial
instruments: Disclosures and Presentation'.


2. LOSS PER SHARE


The calculation of the basic and diluted loss per share is based on the loss on
ordinary activities after tax and on the weighted average number of ordinary
shares in issue during the period. The loss and weighted average number of
shares used in the calculations are set out below:

Basic and diluted loss Loss Weighted average Loss per share
per share £'000 number of shares pence

Six months ended 31st
March 2006 (597) 9,232,227 (6.5)

Six months ended 31st
March 2005 (250) 6,684,505 (3.7)

15 months ended 30th
September 2005 (607) 6,952,913 (8.7)


3. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS/ (DEFICIT)

6 months 6 months 15 months
Ended Ended Ended
31 March 2006 31 March 2005 30 September 2005
Unaudited Unaudited Audited
£'000 £'000 £'000

Loss for the financial
period (597) (250) (607)
Issue of ordinary share
capital 72 5 10
Premium on shares issued
during the period net of
expenses 3441 226 419
Net increase (decrease) in
shareholders'
funds/(deficit) 2916 (19) (178)
Shareholders' funds/
(deficit) at beginning of
period (218) (134) (40)
Shareholders' funds/
(deficit) at end of period 2698 (153) (218)


NOTES TO THE INTERIM STATEMENT continued


For the six months ended 31 March 2006


4. NET CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES

6 months 6 months 15 months
Ended Ended Ended
31March 2006 31March 2005 30 September 2005
Unaudited Unaudited Audited
£'000 £'000 £'000

Operating (loss) (605) (250) (607)
Depreciation 1 1 2
(increase) in debtors (11) (53) (199)
Increase in creditors - 30 115
Increase in provisions - 94 236
Net cash (outflow) from
operating activities (615) (178) (453)


5. RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS

6 months 6 months 15 months
Ended Ended Ended
31 March 2006 31 March 2005 30 September 2005
Unaudited Unaudited Audited
£'000 £'000 £'000

Increase / (decrease) in cash
in the period 2904 53 (25)
Movement in net funds 2904 53 (25)
Opening net funds 29 52 54
Closing net funds 2933 105 29


6. FINANCIAL COMPARATIVES


The comparatives for the 15 month period ended 30 September 2005 are not the
Company's full statutory accounts for that period. A copy of the statutory
accounts for that period was delivered to the Registrar of Companies. The
auditors' report on those accounts was unqualified and did not contain a
statement under section 237(2)-(3) of the Companies Act 1985.


This information is provided by RNS
The company news service from the London Stock Exchange

[outsider] 28/2/2006 20:53

Shares in newly-listed Phynova fell 12.5p to 120p on their second day of trade. Monisha Varadan of leading IPO website allnewissues.com had suggested that the shares were overvalued. The alternative drugs company, which specialises in Chinese botanical medicine, raised 3.65 million pounds through a placing at 77p a share. Allnewissues said that Ofex-listed stock China Biotech was much cheaper. With warrants over 7 million shares, all of which are in the money, Phynova continues to look overcooked

[mirandaj] 28/2/2006 10:58

Note their Scientific adviser:

Brian Whittle PhD, Scientific Director, GW Pharmaceuticals plc
Brian has over 40 years' experience in the pharmaceutical industry and was co-founder of Phytopharm and GW Pharmaceuticals plc

[outsider] 28/2/2006 10:48

Agree, I put Mkt cap of £10.7m above for China Biotech, now edited....of course should read £4.7m

[ltinvestor] 28/2/2006 08:46

According to Ofex China Biotech mkt cap £4.7m and profitable.In my opinion a much better investment.

[outsider] 27/2/2006 21:58

circa 7 million warrants 'in the money' with Phynova too!

China Biotech far better value at this stage.

[outsider] 27/2/2006 21:24

From all new issues:

"There is a temptation to immediately compare this company to OFEX traded China Biotech. A company involved in a similar line of business, though one that is actually run by Chinese botanical medicinal experts".


"Though the OFEX traded company clearly wins on financials as it is not only profitable, but growing fast. Financials for Phynova for the 15 months to 30th September saw losses of £606,653 racked up."